Chicago - 5/1/2023
Aerogen has been awarded a group purchasing agreement for Respiratory Therapy: Medication Delivery and Bronchial Hygiene with Premier, Inc. Effective May 1, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the Aerogen portfolio of products and solutions.
“We are excited to provide our technology and customer support to Premier, their valued members, and the clinicians that serve patients so well” said Brant Nave, Vice President of Commercial Sales at Aerogen. “As Aerogen continues to grow, our commitment to improve patient outcomes remains at the forefront of all that we do.”
Aerogen can be used across multiple modalities for ventilated and non-ventilated patients.1At the heart of every Aerogen device is our unique palladium vibrating mesh technology. Our technology has been awarded the Zenith Award by AARC for the last 9 years.
“Aerogen is honored to be awarded this agreement with Premier in the Respiratory Therapy category” said John Power, Aerogen Founder & Chief Executive. “This agreement helps further our commitment to being the world’s leading aerosol drug delivery system.”
Premier, Inc. is a leading healthcare improvement company, uniting an alliance of more than 4,400 U.S. hospitals and health systems and approximately 250,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost.
About Aerogen
Headquartered in Galway, Aerogen is the world leader in acute care aerosol drug delivery. †2 With a global team of over 400 people the company has offices in the US, China, Germany, UAE, France, and India. Since opening a regional office in Chicago in 2015, Aerogen has grown its North America team significantly to better support this region. With over 20 years of experience, 300 international patents, and 200+ publications, Aerogen technology has been used to treat over 16 million patients in 75 countries worldwide.2
† Global market presence in 75+ countries worldwide
1. 30-674 Rev P Aerogen Solo System Instruction Manual.
2. Aerogen data on file.
